Specialized peptide encapsulation in LNPs for therapeutic peptides, bioactive peptides, peptide antigens, cell-penetrating peptides, cyclic peptides, and peptide-based research payloads.
Peptides offer highly specific biological activity, but their delivery performance is often limited by enzymatic degradation, poor membrane permeability, short retention, aggregation, adsorption loss, and formulation instability. Lipid nanoparticles provide a tunable platform for protecting peptide payloads and improving their suitability for cellular, tissue-oriented, and formulation-development studies. However, peptide encapsulation in LNPs is not a simple extension of nucleic acid encapsulation. Peptide length, net charge, hydrophobicity, secondary structure, terminal modification, disulfide bonding, salt form, solubility, and lipid-binding behavior can strongly affect encapsulation efficiency, particle size, PDI, payload retention, and release profile. BOC Sciences provides peptide encapsulation in LNPs services covering formulation feasibility assessment, lipid composition design, microfluidic encapsulation, encapsulation efficiency optimization, free peptide removal, payload retention testing, and physicochemical characterization. Our service helps pharmaceutical and biotechnology researchers convert sensitive or difficult-to-deliver peptide molecules into stable, well-characterized LNP systems for discovery, screening, and preclinical research applications.
Peptide payloads differ widely in molecular weight, charge distribution, amphiphilicity, conformation, and degradation sensitivity. A formulation that works for a short hydrophilic peptide may fail completely for a cyclic, cationic, amphipathic, or hydrophobic peptide. BOC Sciences provides payload-specific peptide LNP encapsulation services to help researchers identify practical formulation windows, improve peptide loading, reduce free payload interference, and obtain LNP samples suitable for downstream in vitro and in vivo research evaluation.
Many therapeutic peptide candidates show potent biological activity but limited stability, rapid degradation, or poor cellular entry. We develop peptide-loaded LNPs with controlled particle attributes and payload protection to support early delivery evaluation and formulation comparison.
Highly water-soluble peptides often remain in the external aqueous phase during LNP formation, resulting in low encapsulation efficiency and misleading biological readouts. We design formulation strategies to enhance peptide-lipid association and improve internal payload retention.
Hydrophobic or amphipathic peptides may partition into lipid domains but can also cause particle fusion, precipitation, or broad size distribution if the lipid environment is not properly balanced. We support hydrophobic payload encapsulation in LNPs for peptide molecules requiring lipid-phase compatibility optimization.
Cationic and cell-penetrating peptides can interact strongly with lipid membranes, nucleic acids, proteins, and assay components. We help researchers formulate these peptides into LNPs while controlling surface charge, particle uniformity, and non-specific aggregation.
Conformationally constrained peptides may show improved target binding but can present formulation challenges due to rigidity, hydrophobic patches, or low aqueous compatibility. We develop LNP encapsulation strategies that preserve peptide structure while improving dispersion and retention.
Peptide antigens and epitope fragments may require controlled formulation to improve protection, uptake, and presentation-related research performance. We prepare peptide antigen-loaded LNPs for immunology research, antigen delivery evaluation, and formulation comparison studies.
Some projects require both peptide payload encapsulation and LNP surface modification. BOC Sciences supports formulation strategies that combine encapsulated peptide cargo with ligand-modified, PEGylated, or peptide-functionalized lipid nanoparticle designs.
Peptides are often studied in combination with small molecules, nucleic acids, proteins, or imaging components. We provide feasibility screening for co-encapsulated LNP systems where payload compatibility, ratio control, and analytical separation are critical.
BOC Sciences supports peptide-focused encapsulation technologies covering formulation method selection, peptide-specific loading control, post-processing, and analytical characterization.
Move from low-loading, unstable, or assay-interfering peptide formulations to data-guided LNP encapsulation with controlled particle attributes and payload-specific analytical confirmation.
BOC Sciences provides customized peptide LNP encapsulation services according to peptide physicochemical properties, sequence length, structural complexity, and formulation objectives.
| Peptide Category | Supported LNP Systems, Customization Scope & Deliverables | Request Information |
|---|---|---|
| Short Peptide LNPs | Designed for short peptide sequences, epitope peptides, signaling peptides, enzyme-substrate peptides, and small peptide fragments that may show high aqueous solubility and rapid diffusion out of the nanoparticle structure. We optimize lipid composition, peptide-to-lipid ratio, pH, ionic strength, and purification conditions to improve encapsulation efficiency and reduce free peptide. Deliverables may include short peptide-loaded LNP samples, particle size/PDI data, zeta potential when applicable, peptide loading results, and free peptide assessment. | Inquiry |
| Medium-Length Peptide LNPs | Suitable for peptide candidates with moderate sequence length, balanced solubility, and defined biological activity. These peptides may require careful control of charge interaction, lipid-domain partitioning, and post-formulation retention. BOC Sciences screens peptide feeding strategy, buffer conditions, and lipid molar ratios to obtain LNPs with improved loading, controlled particle attributes, and research-ready characterization data. | Inquiry |
| Long Peptide LNPs | Developed for long peptide chains, multi-epitope peptides, peptide domains, and structurally sensitive peptide payloads that may show folding, aggregation, adsorption, or low recovery during formulation. We design gentle encapsulation and buffer exchange workflows, evaluate solvent exposure, and optimize lipid composition to improve peptide retention while controlling particle size distribution and colloidal stability. | Inquiry |
| Hydrophilic Peptide LNPs | Intended for highly water-soluble peptides that tend to remain in the external aqueous phase during LNP formation. We improve peptide-lipid association through charge-regulated encapsulation, buffer pH adjustment, ionic strength screening, and lipid composition optimization. Deliverables focus on reducing free peptide, improving loading consistency, and providing reliable analytical confirmation of encapsulated peptide content. | Inquiry |
| Hydrophobic Peptide LNPs | Designed for hydrophobic peptides, lipid-interacting peptides, amphipathic sequences with strong membrane affinity, and peptides that preferentially partition into lipid-rich domains. We evaluate organic-phase compatibility, solvent displacement conditions, helper lipid ratio, cholesterol level, and microfluidic mixing parameters to improve core loading while minimizing precipitation, turbidity, and broad PDI. | Inquiry |
| Charged Peptide LNPs | Supports cationic, anionic, and zwitterionic peptides whose encapsulation is strongly influenced by electrostatic interaction, pH, salt form, and lipid charge balance. We screen ionizable lipid content, charged lipid ratio, peptide input concentration, and buffer conditions to improve internal association while avoiding overcharged particle surfaces, aggregation, and excessive peptide adsorption. | Inquiry |
| Amphipathic Peptide LNPs | Suitable for peptides with both hydrophilic and hydrophobic domains, including membrane-active peptides, cell-penetrating sequences, and amphipathic helical peptides. These payloads may improve lipid association but can also destabilize the LNP membrane if not properly controlled. We optimize lipid-domain partitioning, PEG-lipid content, peptide-to-lipid ratio, and mixing conditions to balance loading efficiency and particle stability. | Inquiry |
| Cyclic and Constrained Peptide LNPs | Developed for cyclic peptides, stapled peptides, disulfide-constrained peptides, and other structurally restricted peptide payloads. These molecules may show improved biological relevance but can present formulation challenges due to hydrophobic patches, rigidity, poor solubility, or aggregation tendency. We evaluate solvent compatibility, lipid composition, loading route, and retention behavior to obtain stable peptide-loaded LNPs with supporting characterization data. | Inquiry |
Peptide LNP projects often fail because peptide chemistry, lipid selection, purification, and analytical readouts are optimized separately. We address formulation problems as interconnected variables.
✔ Low Encapsulation Efficiency
Highly soluble peptides may remain outside LNPs, while hydrophobic peptides may precipitate before stable particle formation. We screen lipid composition, peptide input, pH, ionic strength, and mixing conditions to improve loading while tracking particle quality.
✔ Peptide Aggregation or Precipitation
Amphipathic or hydrophobic peptides may self-associate during solvent transition, causing turbidity and broad particle size distribution. We adjust peptide feeding strategy, lipid environment, and buffer composition to reduce aggregation risk.
✔ Broad PDI and Poor Batch Reproducibility
Peptide-lipid interaction can disrupt LNP nucleation and growth, producing inconsistent batches. We optimize total flow rate, flow rate ratio, lipid concentration, and phase composition to improve reproducibility across preparation runs.
✔ Rapid Peptide Leakage
Some peptides show acceptable initial loading but leak during purification, dilution, or storage. We evaluate lipid packing, cholesterol level, PEG-lipid content, and buffer conditions to improve payload retention.
✔ Free Peptide Interference in Bioassays
Residual free peptide can distort cellular uptake, activity, or toxicity-related readouts. We combine purification with free payload removal for LNP encapsulation to improve interpretation of LNP-mediated effects.
✔ High Loading but Poor Functional Response
A high loading value does not always indicate useful delivery. We interpret peptide loading together with particle size, PDI, surface charge, peptide integrity, release behavior, and in vitro performance-related formulation attributes.
BOC Sciences provides practical experience in peptide LNP formulation, microfluidic encapsulation, free peptide analysis, payload retention testing, and particle optimization to help researchers develop more stable and reproducible peptide-loaded LNP systems.
We review peptide sequence length, molecular weight, net charge, hydrophobicity, modification status, salt form, solubility, stability concerns, available quantity, and target particle attributes to define a realistic encapsulation strategy.
Lipid molar ratios, peptide-to-lipid ratio, buffer pH, ionic strength, total flow rate, flow rate ratio, solvent transition, and peptide input concentration are screened to identify promising formulation windows.
Candidate peptide LNPs are prepared under controlled mixing conditions, followed by removal of residual solvent, reduction of free peptide, and exchange into a formulation-compatible buffer.
We report encapsulation efficiency, particle size, PDI, zeta potential, peptide recovery, free peptide level, retention or release observations, and key formulation recommendations to guide the next development decision.
Challenge: A peptide discovery team submitted a 16-amino-acid hydrophilic peptide with a net positive charge and strong aqueous solubility. The initial LNP formulation showed particle size around 95-120 nm and acceptable PDI, but peptide encapsulation efficiency remained below 35%. After purification, the free peptide signal was still high, making downstream in vitro uptake and activity data difficult to interpret.
Diagnosis: The peptide remained predominantly in the external aqueous phase during LNP self-assembly. Increasing total lipid concentration improved apparent loading only slightly and caused a zeta potential shift toward a more cationic surface, suggesting surface adsorption rather than true internal retention.
Solution: BOC Sciences designed a stepwise screening plan covering three peptide-to-lipid ratios, two aqueous pH conditions, two ionizable lipid levels, and two PEG-lipid percentages. We first adjusted the buffer pH to increase peptide-lipid association during particle formation, then compared lipid compositions to reduce surface-accessible peptide. A mild purification sequence was introduced to remove loosely associated peptide without destabilizing the LNPs. Each condition was assessed by peptide loading analysis, DLS size, PDI, zeta potential, and free peptide measurement before and after purification.
Result: The optimized condition increased peptide encapsulation efficiency to 72-78%, maintained particle size at 80-105 nm, and kept PDI below 0.20 across repeated preparation runs. Free peptide signal after purification decreased by more than 60%, giving the client a cleaner formulation set for cell-based comparison.
Challenge: A biotechnology client developing a cyclic, amphipathic peptide observed visible turbidity during formulation. Initial batches showed particle sizes above 220 nm, PDI values frequently above 0.35, and inconsistent peptide recovery after buffer exchange. The peptide was intended for intracellular target engagement research, but the broad particle distribution prevented reliable formulation comparison.
Diagnosis: The peptide showed strong hydrophobic self-association during solvent dilution and likely inserted unevenly into lipid domains. The original formulation introduced the peptide directly into the aqueous phase, causing local precipitation before stable LNP assembly could occur.
Solution: Our team compared aqueous-phase feeding, organic-phase co-dissolution, and split-feeding strategies. We then screened helper lipid ratios, cholesterol levels, and total lipid concentration to identify a lipid environment that could accommodate the peptide without triggering fusion. Microfluidic flow conditions were adjusted to shorten the peptide precipitation window during solvent transition. Candidate formulations were evaluated by turbidity observation, DLS, PDI, zeta potential, peptide recovery, and short-term retention after dilution.
Result: The best-performing formulation used organic-phase peptide introduction with a modified helper lipid/cholesterol balance. The final peptide LNPs showed particle size of 90-115 nm, PDI below 0.22, and peptide recovery above 80% after buffer exchange. Compared with the starting condition, visible precipitation was eliminated and the client received a reproducible formulation panel for intracellular delivery evaluation.
Peptide-Specific Formulation ExpertiseWe design LNP encapsulation strategies according to peptide length, charge, hydrophobicity, amphiphilicity, structural rigidity, and degradation sensitivity, helping clients avoid one-size-fits-all formulation approaches.
Comprehensive Characterization CapabilitiesWe evaluate peptide-loaded LNPs using integrated particle and payload readouts, including particle size, PDI, zeta potential, peptide loading, encapsulation efficiency, peptide recovery, free peptide level, retention, and release behavior.
Data-Guided Encapsulation OptimizationInstead of relying on single-condition preparation, we compare lipid composition, peptide-to-lipid ratio, buffer pH, ionic strength, solvent transition, flow rate ratio, and purification conditions to identify practical formulation windows.
Clear Free Peptide DifferentiationWe distinguish encapsulated, surface-associated, and free peptide fractions through suitable separation-assisted, LC-based, fluorescence-based, or colorimetric strategies, helping clients reduce misleading loading values and assay interference.
Flexible Project Scope and DeliverablesBOC Sciences supports feasibility batches, multi-condition formulation screening, peptide retention studies, characterized LNP sample preparation, and broader peptide LNP development programs according to research objectives.
Peptides are attractive biological payloads because they can support receptor targeting, immune modulation, intracellular signaling studies, antimicrobial research, and functional cell-based assays. However, many peptides are vulnerable to enzymatic degradation, rapid diffusion, poor membrane permeability, adsorption loss, and limited stability in biological media. Encapsulation in lipid nanoparticles can help protect peptide payloads, improve particle-associated delivery, and provide a controllable formulation platform for comparing uptake, retention, and functional response. For short peptides, charged peptides, hydrophobic peptides, antigenic peptides, or modified peptides, LNP formulation can also help researchers evaluate how lipid composition, peptide-to-lipid ratio, particle size, and surface properties influence downstream performance.
Peptide LNP encapsulation is challenging because peptides vary widely in sequence length, charge distribution, hydrophobicity, solubility, secondary structure tendency, and chemical modification. A short hydrophilic peptide may leak from particles after dilution, while a hydrophobic peptide may trigger aggregation or broad particle size distribution. Strongly cationic peptides can interact excessively with charged lipids, causing particle instability or surface adsorption rather than true encapsulation. Peptides containing disulfide bonds, cyclic structures, fluorescent labels, fatty acid chains, or targeting motifs may require additional formulation control. A successful strategy must therefore balance loading efficiency, particle uniformity, peptide recovery, free peptide removal, and retained biological relevance.
Peptide loading should be evaluated with methods that distinguish total peptide, free peptide, surface-associated peptide, and particle-associated or encapsulated peptide. Depending on the peptide structure and label, analysis may include HPLC-based quantification, fluorescence measurement, disruption-based loading assessment, filtration or dialysis comparison, zeta potential shift, particle size monitoring, and functional readouts in cell-based assays. For fluorescent peptides, signal quenching, dye leakage, and non-specific adsorption must be considered. For unlabeled peptides, chromatographic or mass-related methods may be more suitable. Reliable characterization should confirm not only how much peptide is present, but also whether the peptide remains associated with stable LNP particles after purification, dilution, or buffer exchange.
LNP encapsulation can be explored for a broad range of peptide payloads, including linear peptides, cyclic peptides, antigenic peptides, cell-penetrating peptides, antimicrobial peptides, targeting peptides, signaling peptides, enzyme-substrate peptides, fluorescently labeled peptides, lipidated peptides, PEGylated peptides, glycopeptides, and other chemically modified peptides. Each peptide type requires a different formulation logic. Antigenic peptides may require conditions that preserve epitope-related features, while hydrophobic peptides may require solubility and aggregation control. Targeting peptides may be used either as encapsulated payloads or as surface-functional ligands. BOC Sciences designs peptide LNP formulation studies according to peptide sequence properties, intended application, and analytical requirements.
BOC Sciences develops peptide LNP formulations through stepwise screening rather than relying on a single fixed condition. Key variables may include ionizable or charged lipid content, helper lipid ratio, cholesterol level, PEG-lipid percentage, peptide-to-lipid ratio, aqueous phase pH, ionic strength, peptide input concentration, microfluidic mixing parameters, purification method, and buffer exchange conditions. Candidate formulations can be compared using particle size, PDI, zeta potential, peptide loading, free peptide content, sample recovery, short-term retention, and suitability for downstream in vitro evaluation. For peptides prone to leakage or adsorption, we can further compare lipid matrix designs and separation strategies to identify more stable, interpretable peptide-loaded LNP samples.
